R&D | October 28, 2025
Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
